Physician profile
Caroline Hwang
NPI 1003090085
$278,584.86
in general payments reported to CMS, 2019-2025
28 companies · $89K in 2025
The $89K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44K · 2020: $18K · 2021: $17K · 2022: $53K · 2023: $26K · 2024: $32K · 2025: $89K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $122K · Food and Beverage: $12K · Travel and Lodging: $11K · Consulting Fee: $300 · Education: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $122,483.50 |
| Food and Beverage | $12,113.75 |
| Travel and Lodging | $11,021.01 |
| Consulting Fee | $300.00 |
| Education | $262.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $84,391.02 | 2021-2025 | |
| Janssen Biotech, INC. | $65,653.74 | 2020-2025 | Tremfya, Stelara, Simponi |
| E.R. Squibb & Sons, L.L.C. | $46,481.91 | 2021-2023 | Zeposia |
| Janssen Scientific Affairs, LLC | $43,900.65 | 2019-2022 | |
| Pfizer INC. | $33,987.48 | 2019-2025 | |
| Celgene Corporation | $1,961.17 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $529.92 | 2021-2025 | Entyvio |
| Lilly USA, LLC | $439.57 | 2023-2025 | Omvoh |
| Cook Medical LLC | $256.16 | 2024-2025 | Echotip Insight, Hemospray |
| Celltrion USA INC. | $181.26 | 2024-2025 | Vegzelma, Zymfentra |
| Genzyme Corporation | $154.64 | 2023-2025 | |
| Medtronic USA, INC. | $138.90 | 2020 | |
| Aimmune Therapeutics, INC. | $76.46 | 2025 | Vowst |
| Covidien LP | $75.43 | 2019 | |
| Welch Allyn | $64.42 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $49.35 | 2024-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.25 | 2022-2023 | Xifaxan |
| Braintree Laboratories, INC. | $34.51 | 2024-2025 | Suflave, Sutab |
| Vivus LLC | $24.74 | 2020 | |
| Qol Medical, LLC | $23.39 | 2024 | Sucraid |
| Merck Sharp & Dohme LLC | $21.40 | 2020 | |
| Fresenius Kabi USA, LLC | $21.36 | 2023 | |
| Ferring Pharmaceuticals INC. | $20.66 | 2023 | Rebyota |
| Phathom Pharmaceuticals, INC. | $18.57 | 2024 | Voquezna |
| Medtronic, INC. | $17.75 | 2024 | Pillcam |
| Daiichi Sankyo INC. | $17.15 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Hwang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.